{
  "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
  "docSlug": "a4fc5169399f8913c54f14d18031629c",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 62,
  "pageCount": 64,
  "prevPage": 61,
  "nextPage": 63,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a combination of expert testimonials and a comparative clinical trial table to validate the outpatient therapy thesis.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/62",
  "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
  "deckJsonHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917.json",
  "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-62",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "callout",
      "text": "02 Administration of Tecvayli will “not be the same as in MajeSTEC-1”",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d7984ae-4981-403c-86ca-c894358c128a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "callout",
      "text": "01 Outpatient Tecvayli “safe and feasible”",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "819d840b-aa03-42dd-aaf9-84197e9f245e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.05,
        "x": 0.28,
        "y": 0.18
      },
      "kind": "image",
      "text": "Asya Nina Varshavsky-Yanovsky, MD, PhD",
      "attrs": null,
      "subkind": "headshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5bab6f0-38d3-4bd4-829f-18d94b0508a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.38,
        "y": 0.43
      },
      "kind": "quote",
      "text": "teclistamab has been approved based on the MajeSTEC-1 study... I'm convinced that's not how we'll be using teclistamab in the future",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6543dcd6-c3f2-418e-9524-ba4e0e76263c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.75,
        "y": 0.43
      },
      "kind": "quote",
      "text": "We learned how to give patients daratumumab [Darzalex]. Initially, there were a lot of infusion reactions. Now everybody feels very comfortable",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b67e391a-b272-4761-a148-a2b6575ddc57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.55,
        "x": 0.42,
        "y": 0.2
      },
      "kind": "quote",
      "text": "We have treated over 20 patients with our outpatient [Teclistamab dosing] program so far... outpatient Teclistamab, step up administration model with close monitoring is safe and feasible",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb74a072-d97b-4b99-a09d-2f257694a056",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.75,
        "x": 0.2,
        "y": 0.7
      },
      "kind": "table",
      "text": "Clinical trial comparison table for NCT05972135 and NCT06015542",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "084296ac-e3b9-45c2-9021-6d4a3efa738b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "BCMA Bispecific Antibodies (Tecvayli, Elrexfio) Are Currently Being Investigated As An Outpatient Therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5cad18a8-baa8-4e36-aa78-ba1fbe95ee1e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}